GSK's Votrient prolongs survival of ovarian-cancer patients in trial

06/4/2013 | Pharmaceutical Business Review Online

GlaxoSmithKline's Votrient, or pazopanib, achieved the main goal of a late-stage trial by extending progression-free survival in patients with advanced epithelial ovarian cancer. Women who received Votrient following front-line chemotherapy survived an average of 17.9 months without their disease worsening versus an average of 12.3 for patients who received a placebo.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC